Diclofenac rapid release - Nautilus Neurosciences

Drug Profile

Diclofenac rapid release - Nautilus Neurosciences

Alternative Names: PRO-571

Latest Information Update: 24 Nov 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Applied Pharma Research
  • Developer Nautilus Neurosciences
  • Class Antirheumatics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 01 Nov 2014 Discontinued - Phase-I for Pain in USA (PO)
  • 15 Dec 2009 Diclofenac rapid release licensed to Nautilus Neurosciences
  • 04 Aug 2008 ProEthic Pharmaceuticals has been acquired by Kowa
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top